Matias Emanuel Valsecchi

PT1.08.03 Chemoradiation/Immunotherapy(IO) for Stageiii NSCLC: Timing of IO, and the Benefits/Selection in Elderly & Black Patients

Howide Eldib, Rick P. Voland, Jean Flickinger, M Decamp et autres

us (code pays fourni par la source)

Evaluation of Anti-Angiogenic Therapy Combined with Immunotherapy and Chemotherapy as a Strategy to Treat Locally Advanced and Metastatic Non-Small-Cell Lung Cancer

Mahmoud Abdallah, Rick P. Voland, Malcolm M. DeCamp, John C. Flíckinger et autres

Immunotherapy has made recent improvements in disease-free survival (DFS) and/or overall survival (OS) in all stages of non-small-cell lung cancer (NSCLC). Here, we review the tumor microenvironment and its immunosuppressive effects and discuss how anti-angiogenic therapies may potentiate the anti-carcinogenic effects of …

us (code pays fourni par la source)

A randomized phase II study of adjuvant sunitinib or valproic acid in high-risk patients with uveal melanoma.

Takami Sato, Marlana M. Orloff, Matias Emanuel Valsecchi, Ayako Shimada et autres

e22059 Background: Uveal melanoma is the most common primary intraocular cancer in adults. Despite successful treatment of primary tumors, up to 50% of patients later die of distant metastases. Currently, no effective adjuvant treatment is available. Presence of both monosomy 3 and …

us (code pays fourni par la source)

Precision therapeutic targeting of human cancer cell motility

Li Xu, Ryan R. Gordon, Rebecca Farmer, Abhinandan Pattanayak et autres

Increased cancer cell motility constitutes a root cause of end organ destruction and mortality, but its complex regulation represents a barrier to precision targeting. We use the unique characteristics of small molecules to probe and selectively modulate cell motility. By coupling efficient …

us, cn (code pays fourni par la source)

Adjuvant Sunitinib in High-Risk Patients with Uveal Melanoma

Matias Emanuel Valsecchi, Marlana M. Orloff, Rino Sato, Inna Chervoneva et autres

us (code pays fourni par la source)

Editorial (Mini Thematic Issue: Immunotherapy – A Pivotal Mechanism in the Fight of Cancer)

Matias Emanuel Valsecchi

Immunotherapy for Non-Small Cell Lung Cancer - Finally a Hint of Hope

Gonzalo Recondo, Fernando Galanternik, Martín Greco, Martha Vega et autres

Lung cancer is a major public health problem worldwide and the leading cause of cancerrelated mortality in developed countries. Significant advances have been made especially with the discovery of targeted agents. However, only a small proportion of patients carry activating mutations; until …

ar, us (code pays fourni par la source)

Immune Check Point Inhibitors Combination in Melanoma: Worth the Toxicity?

Marlana M. Orloff, Ryan Michael Weight, Matias Emanuel Valsecchi, Takami Sato

The combination of immune checkpoint inhibitors ipilimumab and nivolumab has been recently been FDA approved for first line treatment of unresectable and metastatic BRAF wild type melanoma. The approval came following the impressive results of the CheckMate 067, where the combination of …

us (code pays fourni par la source)

What is the Current Role of Immunotherapy for Colon Cancer?

Fernando Galanternik, Gonzalo Recondo, Matias Emanuel Valsecchi, Martín Greco et autres

Colon cancer is a leading cause of cancer related mortality. Until very recently the only existing options that medical oncologists had to treat metastatic colon cancer were a combination of chemotherapy, anti-EGFR and anti-angiogenic agents. We currently have the first proof that …

ar (code pays fourni par la source)

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Matias Emanuel Valsecchi

BACKGROUNDNivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] checkpoint inhibitor) have been shown to have complementary activity in metastatic melanoma.In this randomized, double-blind, phase 3 study, nivolumab alone or nivolumab plus ipilimumab was compared …

Role of Carboplatin in the Treatment of Triple Negative Early- Stage Breast Cancer

Matias Emanuel Valsecchi, Gerrit A. Kimmey, Arvinder Bir, Damian Silbermins

Triple negative breast cancer (TNBC) is more prevalent in younger patients and those carrying BRCA mutations. Although the incidence of breast cancer in general has dropped during the last years, TNBC has shown a relative increase. It is recognized as a breast …

us (code pays fourni par la source)

Anti-Hormonal Therapies for Premenopausal Patients – What did we Learn from the TEXT/SOFT Trials?

Matias Emanuel Valsecchi, Gonzálo Recondo, Martha Vega, Martín Greco et autres

Between 20-25% of all breast cancers are diagnosed in patients younger than 50 years of age, most of whom are still premenopausal. Currently, tamoxifen is considered the standard of care for adjuvant treatment in these cases. However, in postmenopausal women, aromatase inhibitors …

ar (code pays fourni par la source)